Erwann P. Loret

Unité Mixte De Recherche CNRS 7263 IRD 237 Faculté St Jérôme, Avenue Escadrille Normandie Niemen, CEDEX 20
Marseille, 13397, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Ulva lactuca, A Source of Troubles and Potential Riches.

Ulva lactuca, A Source of Troubles and Potential Riches.

Journal: Marine drugs
Published: April 17, 2019

Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat.

Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat.

Journal: mBio
Published: February 07, 2019

A Low Molecular Weight Protein from the Sea Anemone Anemonia viridis with an Anti-Angiogenic Activity.

A Low Molecular Weight Protein from the Sea Anemone Anemonia viridis with an Anti-Angiogenic Activity.

Journal: Marine drugs
Published: March 16, 2018

Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Journal: Retrovirology
Published: May 11, 2016

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Journal: Retrovirology
Published: February 01, 2016

HIV extracellular Tat: myth or reality?

HIV extracellular Tat: myth or reality?

Journal: Current HIV research
Published: July 18, 2014

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Journal: Vaccine
Published: June 10, 2014

Identification of a highly conserved surface on Tat variants.

Identification of a highly conserved surface on Tat variants.

Journal: The Journal of biological chemistry
Published: May 17, 2013

A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.

A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.

Journal: The Journal of biological chemistry
Published: February 25, 2012
Showing 1-9 of 9

Last Updated: 09/26/2026